Reported by G-MedTech News Center / Sep 27, 2023
South Korea Seoul-based HoneyNaps has received US FDA clearance for its SOMNUM AI sleep disorder analysis algorithm, which goes beyond conventional video image reading systems for biosignals by using deep learning-based AI to perform real-time analysis of large volumes of multi-channel/time series biosignals, setting a new standard for accuracy and transparency in the field.
Sleep biosignals typically include electroencephalograms, electrooculograms, chin and leg electromyograms, electrocardiograms, respiratory airflow and effort, oxygen saturation, posture, and snoring, which are continuously monitored to assess sleep status and diagnose sleep disorders via polysomnography that takes up to three to four hours by skilled personnel to read. AI reading systems have been extensively researched to overcome the staffing and time barriers.
AI reading technology for biosignals is expected to play a very important role, and with its continuous improvement, it will be possible to detect or predict some cardiovascular, neurological and muscular diseases beyond the diagnosis of sleep disorders,” said Professor Ji Ho Choi, head of the Sleep Medicine Centre at Soonchunhyang University Bucheon Hospital.
By integrating the latest AI research trends with diagnostic algorithms based on multi-channel/time series sleep biosignal data rather than by reading video images, HoneyNaps is paving the way for the future of AI in healthcare.